SCHEMBL11173

SCHEMBL11173

COc1cc(Br)ccc1C=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.63
ERN1 O75460 4/20 0.58
TSHR P16473 2/20 0.55
KDM4E B2RXH2 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
PRKDC P78527 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
TRIM24 O15164 1/20 0.43
TYR P14679 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
TLR2 O60603 1/20 0.43
TLR1 Q15399 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30178662 1.00 ALDH1A1 (0.63) ALDH1A1ERN1TSHRKDM4ETDP1
SCHEMBL2636617 0.90 ALDH1A1 (0.53) ALDH1A1ERN1TSHRKDM4ETDP1
SCHEMBL6093571 0.85 ERN1 (0.46) ALDH1A1ERN1TSHRKDM4ETDP1
SCHEMBL153974 0.84 ERN1 (0.58) ALDH1A1ERN1TSHRKDM4ETDP1
SCHEMBL29890082 0.84 ERN1 (0.58) ALDH1A1ERN1TSHRKDM4ETDP1
SCHEMBL28988651 0.83 CYP1A2 (0.47) ALDH1A1ERN1TSHRKDM4ETDP1
SCHEMBL17426244 0.82 ERN1 (0.56) ALDH1A1ERN1TSHRKDM4ETDP1
SCHEMBL21352066 0.82 TUBB4A (0.46) ALDH1A1ERN1KDM4ETDP1L3MBTL1
SCHEMBL27890878 0.82 ERN1 (0.48) ALDH1A1ERN1TDP1PRKDCL3MBTL1
SCHEMBL46203 0.81 ALDH1A1 (0.55) ALDH1A1ERN1PRKDCL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118027327-B COFs material capable of improving carrier separation efficiency and preparation method and application thereof 生态环境部南京环境科学研究所 2024-10-25 CN claimed
CN-118027327-A COFs material capable of improving carrier separation efficiency and preparation method and application thereof 生态环境部南京环境科学研究所 2024-05-14 CN claimed
CN-117945947-A Synthesis method of 2-methoxy-4-cyanobenzaldehyde 江西凯信生物医药有限公司 2024-04-30 CN claimed
CN-117924273-A Preparation method of non-neridrone bulk drug 江苏德源药业股份有限公司 2024-04-26 CN claimed
CN-117304067-A Synthesis method of non-nefardone intermediate 4-cyano-2-methoxybenzaldehyde 南京工业大学 2023-12-29 CN claimed
CN-116082334-A Preparation method of non-neridrone and intermediate thereof 上海新礼泰药业有限公司 2023-05-09 CN claimed
CN-116041347-A Preparation method of non-nereirenone intermediate 上海新礼泰药业有限公司 2023-05-02 CN claimed
CN-111233908-A Benzoxaborol-1-ol compound and preparation method and application thereof 南京农业大学 2020-06-05 CN claimed
EP-2593419-A1 PROCESSES FOR PRODUCING 4-BROMO-2-METHOXYBENZALDEHYDE Albemarle Corporation (US) 2013-05-22 EP claimed
US-20130090498-A1 PROCESSES FOR PRODUCING 4-BROMO-2-METHOXYBENZALDEHYDE ALBEMARLE CORPORATION (US) 2013-04-11 US claimed
WO-2012009173-A1 PROCESSES FOR PRODUCING 4-BROMO-2-METHOXYBENZALDEHYDE ALBEMARLE CORPORATION (US) 2012-01-19 WO claimed
US-20260124191-A1 HISTONE DEACETYLASE INHIBITOR AND USES THEREOF NANJING HONGSHUN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2026-05-07 US disclosed
EP-4519384-B1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF PROMEGA CORP (US) 2026-04-29 EP disclosed
EP-4725940-A1 HISTONE DEACETYLASE INHIBITOR AND USE Nanjing Hongshun Pharmaceutical Technology Co., Ltd (CN) 2026-04-15 EP disclosed
EP-4716685-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-04-01 EP disclosed
WO-2002089738-A2 PROTEOMIMETIC COMPOUNDS AND METHODS YALE UNIVERSITY (US) 2002-11-14 WO disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 EP disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 WO disclosed
EP-0417760-A2 Phenylalkanoyl substituted imidazo[4,5-c] pyridines G.D. Searle & Co. (US) 1991-03-20 EP disclosed
US-4988707-A Platelet activating factor, antiinflammatory agents, cardiovascular disorders and treatment of asthma G. D. SEARLE & CO. (US) 1991-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090498-A1 PROCESSES FOR PRODUCING 4-BROMO-2-METHOXYBENZALDEHYDE KCNMB4, KCNB1, KCNMB1 ALDH1A1 761/4885ERN1 2733/4885TSHR 3796/4885
US-20260124191-A1 HISTONE DEACETYLASE INHIBITOR AND USES THEREOF HDAC1, HDAC3, HDAC2 ALDH1A1 2329/4885ERN1 1705/4885TSHR 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.